Pandemic Resilience, Supply & R&D Agreement for mRNA vaccines

The contract is to establish UK-based mRNA vaccine development and manufacturing capability to support the UK's preparedness and resilience for future pandemics and health emergencies. The objective of security of supply in such circumstances is to be met by the construction of a mRNA manufacturing facility sited within the UK which will work alongside UK-based fill/finish providers to supply vaccines. In addition, the contract also includes certain commitments for the supplier to invest in R&D in the field of mRNA vaccines and therapeutics within the UK.